News & Media

282025-03

Mabgeek Biotech has officially moved into WORLO COMPUTING-CHANGSHA INTELLIGENCE VALLEY

312025-10

The marketing application for the indication of moderate to severe atopic dermatitis of MG-K10, the world's first long-acting IL-4Rα monoclonal antibody, has been accepted.

On October 30, 2025, the marketing authorization application for the innovative drug of Class 1, Kem
292025-09

Flash News | Mabgeek Biotech has received the approval notice for the Phase III clinical trial of chronic spontaneous urticaria (CSU)

On September 29, 2025, the innovative monoclonal antibody drug "MG-K10 Humanized Monoclonal Antibody
202025-08

A Solemn Statement on the Fraudulent Use of Our Company's Email by Criminals

Recently, our company has discovered that some lawbreakers are using email addresses highly similar

Technological innovation

Efficient integration; Establish an efficient antigen-antibody expression and purification platform.

All team members come from well-known domestic pharmaceutical companies, and the team has over three years of cooperation experience.

The company has a 500-square-meter laboratory and four cell culture rooms.

Independent R&D and clinical development of innovative antibodies have resulted in the first domestic market launch and the first global submission.

About Us

About
R&D
- Areas
- Pipeline
- Platforms
Publications
- MG-K10
- MG-ZG122
Careers
- Culture
- Join Us

Contact Us

ADD:No.5, Building 34, Lane 122, Chunxiao Road, Zhangjiang Town, Pudong New Area, Shanghai
TEL: +86-21-51371305
EMAlL:info@mabgeek.com

All Rights Reserved by HUNAN MABGEEK BIOTECH CO., LTD © 2018-2024 mabge.com

湘ICP备2024096314号公安部备案：31011502015815